Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, ...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3 clinical trial of CAN-2409 in newly diagnosed, localized …